Designing for Coverage, Not Just Approval
Why early integration of HEOR and payer strategy is essential to reimbursement confidence and predictable launch performance
Regulatory approval has long been treated as the primary inflection point in drug development. It signals scientific validation and market readiness.
In practice, approval represents a regulatory milestone, but coverage decisions follow a separate evaluation process.
In today’s US market, the commercial trajectory of a therapy is shaped as much by payer interpretation of evidence as by regulatory review. Trial design decisions influence not only whether a product can be marketed, but how confidently it will be covered.
When payer expectations are not considered early, questions may remain at the time of coverage decision-making.
Regulatory Standards and Reimbursement Standards Are Not the Same
Regulators evaluate benefit and risk within a defined clinical framework. Approval may be supported by surrogate endpoints, single-arm studies, or accelerated pathways when appropriate.
Payers apply a different lens. They evaluate magnitude of benefit relative to standard of care, durability of outcomes, expected utilization, and financial impact within defined budget cycles.
In the United States, these evaluations occur across a fragmented landscape:
- FDA approval is national
- Coverage decisions are plan-specific
- Commercial plans, PBMs, Medicare, Medicaid, and integrated delivery systems develop independent policies
The result is variability. A therapy may meet regulatory standards yet face materially different access requirements across plans.
That variability reflects how evidence is interpreted within financial and operational constraints.
“Clinical success does not automatically translate into access. Between FDA approval and patient uptake sits a complex set of payer and system-level decisions.”
— Christine Molbury, SVP, Market Access Value & Solutions
Industry Perspective from Webinar Attendees
Which stakeholder most influences access for a therapy in the United States?
38% — Varies significantly by product
29% — Pharmacy Benefit Managers (PBMs)
18% — Commercial health plans
12% — Medicare or Medicaid
3% — Integrated delivery networks (IDNs)
These results highlight how access decision-making often depends on therapy characteristics, payer mix, and market dynamics rather than a single controlling stakeholder.
Source: Poll of webinar attendees during Magnolia Market Access webinar, February 2026.
When clinical evidence is strong, relevant, and aligned with real-world practice, coverage decisions tend to be more straightforward.
Payers consistently respond to:
- Comparator data that reflects actual treatment pathways
- Hard clinical outcomes with clear magnitude of improvement
- Durable benefit
- Representative patient populations
- Clear linkage between outcomes and healthcare resource utilization
When these elements are absent or incomplete, uncertainty is addressed through policy.
Prior authorization criteria often mirror trial inclusion and exclusion parameters. Step therapy requirements frequently default to lower net-cost alternatives in the absence of compelling comparative evidence.
In this environment, evidence gaps become operational controls.
“What is enough for approval is not always enough for confident coverage. The strongest evidence packages translate into real-world value.”
— Anna Hundt Golden, Senior Director Market Access & Value Insights
Industry Perspective from Webinar Attendees
How often do US payers request evidence beyond what is generated in clinical trials?
36% — Often
25% — Almost always
29% — Sometimes
4% — Rarely
7% — Not sure
Key Insight: 61% of webinar attendees report that US payers often or almost always request evidence beyond clinical trial data.
These requests may involve real-world evidence, comparative analyses, or economic evaluation to support coverage discussions.
Source: Poll of webinar attendees during Magnolia Market Access webinar, February 2026.
Coverage decisions are made within financial boundaries.
Short-term budget impact often plays a significant role in coverage evaluations, sometimes alongside cost-effectiveness modeling. Plans assess eligible population size, anticipated uptake, net price, and financial exposure over one- to three-year cycles.
A therapy demonstrating meaningful clinical improvement may still face additional review if projected near-term budget impact is substantial.
This dynamic reinforces the importance of anticipating not only clinical differentiation, but affordability perception.
“Pivotal trials are designed to meet regulatory standards. Payers are focused on budget impact, real-world performance, and comparative value.”
— Jessica Duchen, VP, Real-World Evidence & HEOR Strategy
Trial Design Influences Reimbursement Confidence
Clinical development decisions are often framed around regulatory probability of success. They also influence how payers assess confidence in coverage decisions.
Comparator selection, endpoint hierarchy, inclusion criteria, subgroup analysis, and follow-up duration all shape how payers evaluate value and uncertainty.
When HEOR, market access, RWE, and commercial perspectives are integrated before Phase II protocol finalization, teams can consider payer-relevant evidence needs within trial design.
When these perspectives are incorporated after pivotal trials conclude, organizations often rely on reactive strategies to mitigate uncertainty. From a planning standpoint, early integration can help reduce downstream uncertainty.
Integrating Access Across the Development Lifecycle
Payer considerations should be incorporated throughout development.
Early-phase planning can assess reimbursement landscapes and endpoint relevance.
Mid-phase development can refine comparator strategy and population definitions.
Late-phase planning can strengthen durability data and health system impact measures.
Addressing payer evidence needs during development supports more informed reimbursement discussions at launch.
Key Takeaways for Biopharma Leaders
The Bottom Line
The connection between regulatory approval and access considerations is increasingly visible.
Trial design has both clinical and commercial implications. Evidence that satisfies regulators may not satisfy payers. When payer expectations are addressed early, reimbursement confidence improves.
For biopharma leaders, approval is one milestone in a broader access journey. Increasingly, launch success depends on whether the evidence generated during development aligns with how payers evaluate clinical benefit, affordability, and real-world impact.
Designing with coverage considerations in mind helps bridge the gap between approval and access.
Start a Conversation
Connect with us to explore how integrating HEOR and payer perspectives earlier in development can support stronger reimbursement planning.
Explore the full Magnolia Market Access webinar, Integrating HEOR and Payer Considerations in Clinical Trial Design to Improve Access, for deeper insights into aligning development strategy with reimbursement realities.